Table 3.

Adjusted (for age) outcomes after allogeneic transplant receiving ixazomib plus standard graft-versus-host disease (GVHD) prophylaxis on the study.

Outcomes	Phase II MRD (n=25) Probability (95% CI)	Phase II MUD (n=26) Probability (95% CI)
Chronic GVHD, 1 year	36% (19-54)	39% (21-56)
Moderate/Severe Chronic GVHD, 1 year	28% (13-46)	27% (12-44)
Acute GVHD, grade II-IV, 100 days	20% (8-37)	15% (5-31)
Acute GVHD, grade III-IV, 100 days	8% (1-22)	12% (3-26)
Acute GVHD, grade II-IV, 180 days	28% (13-46)	23% (10-40)
Acute GVHD, grade III-IV, 180 days	8% (1-22)	15% (5-31)
Non-relapse mortality, 1 year	0%	4% (0-16)
Relapse, 1 year	20% (8-37)	35% (18-52)
Relapse-free survival, 1 year	80% (58-91)	62% (40-77)
Overall survival, 1 year	92% (72-98)	89% (68-96)